Herpes simplex research - Wikipedia Herpes simplex research includes all medical research that attempts to prevent, treat, or cure herpes, as well as fundamental research about the nature of herpes Examples of particular herpes research include drug development, vaccines and genome editing HSV-1 and HSV-2 are commonly thought of as oral and genital herpes respectively, but other members in the herpes family include chickenpox
A Clinical Trial in Healthy Volunteers and Volunteers with Recurrent . . . This exploratory trial will have three parts Part A is a dose escalation part, Part B is an expanded safety and dose evaluation part, and Part C is a safety and immunogenicity evaluation part in individuals with recurrent HSV-2 genital herpes Part A will focus on the safety evaluations, and in addition, vaccine-induced immune responses (specifically neutralizing antibodies) will also be
Helicase–Primase Inhibitor Pritelivir for HSV-2 Infection We randomly assigned 156 HSV-2–positive persons with a history of genital herpes to receive one of four doses of oral pritelivir (5, 25, or 75 mg daily, or 400 mg weekly) or placebo for 28 days
A Randomized, Double-Blinded, Placebo-Controlled, Phase 1 . . . - PubMed Background: Herpes simplex virus 2 (HSV2) causes genital herpes in >400 million persons worldwide Methods: We conducted a randomized, double-blinded, placebo-controlled trial of a replication-defective HSV2 vaccine, HSV529 Twenty adults were enrolled in each of 3 serogroups of individuals: those negative for both HSV1 and HSV2 (HSV1- HSV2-), those positive or negative for HSV1 and positive
Phase I Study of a Herpes Simplex Virus Type 2 (HSV-2) DNA Vaccine . . . We conducted a double-blind, vehicle-controlled, dose escalation safety and immunogenicity trial of a candidate herpes simplex virus type 2 (HSV-2) surface glycoprotein D2 (gD2) DNA vaccine administered by use of a needle-free device Sixty-two healthy adults were randomized using a 4:1 vaccine-to-placebo ratio
HSV-2: in pursuit of a vaccine - PMC Two parallel studies showed that a recombinant gD2 subunit vaccine with an alum monophospholipid A adjuvant (AS04) was also safe and induced both neutralizing antibody and CD4 + immune responses () The first trials randomized HSV-2–seronegative persons in a stable HSV-2–discordant sexual relationship, in which the source partner had clinically evident genital herpes, to receive vaccine or
Studies - The University of Washington Virology Research Clinic A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Phase 1 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 Therapeutic DNA Vaccines in Symptomatic HSV-2-Seropositive Adults Study Description: This study is what is known as a randomized clinical trial Randomization means that participants are put
Herpes simplex virus - Wikipedia Herpes simplex virus 1 and 2 (HSV-1 and HSV-2) are two members of the human Herpesviridae family, a set of viruses that produce viral infections in the majority of humans [1] [2] Both HSV-1 and HSV-2 are very common and contagious They can be spread when an infected person begins shedding the virus As of 2016, about 67% of the world population under the age of 50 had HSV-1 [3]
Randomized, Double-Blinded, Placebo-Controlled, Phase 1 Study of a . . . We conducted a randomized, double-blinded, placebo-controlled trial of a replication-defective HSV2 vaccine, HSV529 Twenty adults were enrolled in each of 3 serogroups of individuals: those negative for both HSV1 and HSV2 (HSV1 − HSV2 −), those positive or negative for HSV1 and positive for HSV2 (HSV1 ± HSV2 +), and those positive for HSV1 and negative for HSV2 (HSV1 + HSV2 −)
Clinical trials of prophylactic and therapeutic herpes simplex virus . . . Herpes simplex virus type 2 (HSV-2) is a suitable target for a vaccine, despite available antiviral therapies, because the virus causes lifelong infection and significant medical and psychosocial morbidity A vaccine has the potential to reduce HSV acquisition, disease severity and the number of cas …